Autres langues Stoke Therapeutics, Inc.

Actions

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 17/05/2024			Varia. 5j.	Varia. 1 janv.
13,9 ^USD	-0,93 %		+21,08 %	+164,26 %

07/05	STOKE THERAPEUTICS, INC. : Canaccord Genuity reste à l'achat	ZM
06/05	Stoke Therapeutics, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)	17/05
Stoke Therapeutics : Corporate Presentation - May 2024	06/05
Earnings Flash (STOK) STOKE THERAPEUTICS Reports Q1 Revenue $4.2M	06/05
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates	06/05
Stoke Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	06/05
Stoke Therapeutics Appoints Thomas Leggett CFO	29/04
Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer	29/04
Stoke Therapeutics, Inc. Announces Executive Changes, Effective May 7, 2024	29/04
Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer	17/04
Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer	17/04
Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference	04/04
Sector Update: Health Care Stocks Advance Premarket Thursday	28/03
Stoke Therapeutics Prices Upsized $125 Million Share Offering	28/03
Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering	28/03
North American Morning Briefing : Stocks Edge -2-	27/03
Stoke Therapeutics Plans $75 Million Public Offering	26/03
MÄRKTE USA/Etwas leichter - Zurückhaltung vor Inflationsdaten	26/03
Stoke Therapeutics Announces Proposed Public Offering	26/03
Sector Update: Health Care Stocks Advance Late Afternoon	26/03
Stoke Therapeutics Rises After Investigational Drug Shows Improvement in Dravet Syndrome Patients	26/03

Aucun résultat pour cette recherche